Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant

Supportive Care in Cancer

Volumn 16, Issue 5, 2008, Pages 477-483

  Schuster, Michael W ^a   Shore, Tsiporah B ^a   Harpel, John G ^a   Greenberg, June ^a   Jalilizeinali, Bita ^a   Possley, Scott ^a   Gerwien, Robert W ^b   Hahne, William ^b   Halvorsen, Yuan Di C ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CURAGEN CORPORATION   (United States)

Author keywords

Autologous stem cell transplant; Cancer supportive care; CG53135; Oral mucositis; Velafermin

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; VELAFERMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUSHING; HUMAN; HYPOTENSION; MALE; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; STOMATITIS; TACHYCARDIA; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTORS; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STOMATITIS; TREATMENT OUTCOME;

EID: 41849092234     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0325-9     Document Type: Article

References (20)

1. Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M et al (2003) Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 9(9):3454-3461
2. Alvarez E, Gerlach VL, Gerwien RW, Fey EG, Watkins BA, Hahne WF et al (2005) Single-dose prevention or short-term treatment with fibroblast growth factor-20 (CG53135-05) reduces the severity and duration of oral mucositis. Support Cancer Ther 2(2):122-127
3. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE (2005) FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 24(1):73-84
4. Crawford J, Tomita DK, Mazanet R, Glaspy J, Ozer H (1999) Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 5(4):187-193
5. Dailey L, Ambrosetti D, Mansukhani A, Basilico C (2005) Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16(2):233-247
6. Elting LS, Shih YC (2004) The economic burden of supportive care of cancer patients. Support Care Cancer 12(4):219-226
7. Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR et al (2004) A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 28(6):559-565
8. Jeffers M, Shimkets R, Prayaga S, Boldog F, Yang M, Burgess C et al (2001) Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res 61(7):3131-3138
9. Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL et al (2002) A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 123(4):1151-1162
10. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al (2003) Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 21(8):1452-1458
11. Peterson DE, Cariello A (2004) Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol 31(3 Suppl 8):35-44
12. Peterson DE, Petit RG (2004) Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy. J Clin Oncol 22(14S):8008
13. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026-2046
14. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995-2025
15. Spencer A, Horvath N, Gibson J Prince HM, Herrmann R, Bashford J et al (2005) Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 35(10):971-977
16. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590-2598
17. Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK et al (2004) Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Res 24(5B):3263-3267
18. Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al (2002) Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 30(11):769-775
19. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al (2000) Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 110(2):292-299
20. World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, pp 15-22